Differential effects of vitamin D receptor activators on vascular calcification in uremic rats M. Mizobuchi, J.L. Finch, D.R. Martin, E. Slatopolsky Kidney International Volume 72, Issue 6, Pages 709-715 (September 2007) DOI: 10.1038/sj.ki.5002406 Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 1 Aortic Ca content in normal rats and 5/6 nephrectomized uremic rats treated with vehicle (UC), 0.04 μg/kg of calcitriol (1,25D3), 0.16 μg/kg of doxercalciferol (1αD2), or paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6 or 7). P<0.0001 by analysis of variance. **P<0.01 versus UC; ##P<0.01 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 2 Representative microphotograph of von Kossa staining of aorta from uremic rats treated with vehicle (UC), 0.04 μg/kg of calcitriol (1,25D3), 0.16 μg/kg of doxercalciferol (1αD2), or paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Original magnification at × 400. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 3 Effects of 0.10 μg/kg of doxercalciferol (1αD2) or 0.24 μg/kg of paricalcitol (19-nor) on serum levels of (a) ionized Ca, (b) total Ca, (c) P, and (d) Ca × P product in uremic rats. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). #P<0.05 versus 19-nor by non-paired t-test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 4 Effects of 0.10 μg/kg of doxercalciferol (1αD2) or 0.24 μg/kg of paricalcitol (19-nor) on aortic Ca content in uremic rats. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). ##P<0.01 versus 19-nor by non-paired t-test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 5 Effects of 0.04 μg/kg of calcitriol (1,25D3), 0.10 μg/kg of doxercalciferol (1αD2), or 0.16 μg/kg of paricalcitol (19-nor) on Runx2 mRNA expression levels in aorta from uremic rats. Runx2 mRNA levels were analyzed by real-time RT-PCR technique. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). P<0.01 by analysis of variance. *P<0.05 versus UC; ••P<0.01 and •P<0.05 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 6 Effects of 0.04 μg/kg of calcitriol (1,25D3), 0.10 μg/kg of doxercalciferol (1αD2), or 0.16 μg/kg of paricalcitol (19-nor) on mRNA expression levels in aorta from uremic rats. Osteocalcin mRNA levels were analyzed by real-time RT-PCR technique. Each drug was given intraperitoneally three times a week for 1 month. Values are mean±s.e.m. (n=6). P<0.01 by analysis of variance. **P<0.01 and *P<0.05 versus UC; ••P<0.01 and •P<0.05 versus 19-nor by post hoc, Scheffe test. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions
Figure 7 Representative microphotograph of immunohistochemistry for Runx2 or osteocalcin in aorta from uremic rats treated with 0.10 μg/kg of doxercalciferol (1αD2) or 0.16 μg/kg of paricalcitol (19-nor). Each drug was given intraperitoneally three times a week for 1 month. Original magnification at (a) × 100 and (b) × 200. Kidney International 2007 72, 709-715DOI: (10.1038/sj.ki.5002406) Copyright © 2007 International Society of Nephrology Terms and Conditions